Inke’s Leadership in Respiratory Health – An Interview with CEO Miquel Bachs

October 28, 2024

In a recent conversation with SpeakPharma, Inke’s CEO, Miquel Bachs, discusses the company’s expertise in micronization, its commitment to sustainability, and the evolving role of European innovation in global respiratory health. With over two decades dedicated to advancing respiratory APIs and high-quality solutions, Inke has become a cornerstone in the pharmaceutical industry. Below, Bachs shares Inke’s vision and ongoing contributions to treating respiratory diseases.

Q: Can you talk about Inke’s mission and unique expertise in micronization?

Bachs: At Inke, we specialize in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), primarily focused on respiratory health. Micronization, the process of reducing particle size to enhance efficacy and bioavailability, has been one of our core strengths for over 20 years. This allows us to create pharmaceutical ingredients that are optimized for absorption, which is especially critical for respiratory treatments. Our commitment to innovation and quality enables us to deliver high-performance APIs that meet the needs of both patients and our industry partners.

Q: In terms of growth and global reach, what are Inke’s key markets, and how does the company plan to expand its footprint?

Bachs: Expanding in key markets such as the US, Europe, and Asia remains a top priority for us, with particular focus on the growing opportunities in China, where we have 12 active DMFs. Successfully navigating regulatory requirements in these regions has been central to our strategy, and we continue to invest in compliance and quality assurance. This allows us to meet and exceed regulatory standards, particularly in markets with rigorous compliance expectations like the FDA in the US.

Q: Inke recently launched Contract Manufacturing Organization (CMO) services. How does this align with your strategic goals?

Bachs: Expanding into CMO services was a natural progression for Inke. This service complements our core strengths in API development and particle engineering, allowing us to offer end-to-end solutions tailored to our clients’ unique needs. We provide flexibility in production scale, from small batches to large volumes, enabling us to serve a diverse range of pharmaceutical partners. Our CMO services, paired with our expertise in micronization, offer our clients efficient, high-quality manufacturing that aligns with their regulatory and technical requirements.

Q: How is Inke addressing sustainability, and what role does it play in your long-term vision?

Bachs: Sustainability is integral to our mission at Inke. We’ve adopted a comprehensive Environmental, Social, and Governance (ESG) approach that includes sustainable energy initiatives, such as the recent installation of a 135 kWp solar panel system, and waste reduction measures like water treatment and reuse systems. By incorporating these practices, we align our operations with our commitment to minimizing environmental impact and fostering a sustainable, inclusive workplace. Our focus on ESG not only supports our growth but also contributes positively to the communities and ecosystems in which we operate.

Q: How do you see Inke’s role in advancing the pharmaceutical industry’s approach to respiratory health?

Bachs: With respiratory diseases on the rise globally, our role in developing APIs that support respiratory health is more critical than ever. Inke is focused on creating effective, high-quality solutions for respiratory conditions like COPD and asthma. Our goal is to stay at the forefront of API innovation, working closely with our partners to address both current and future needs in respiratory care. We’re committed to being a driving force in respiratory health, anticipating industry shifts and delivering solutions that enhance patient outcomes worldwide.

To read the full SpeakPharma interview, visit here.